ADMA BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.55 USD | +1.71% |
|
+4.47% | +44.91% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 237.3 | 184.4 | 276.1 | 857.1 | 1,021 | 1,518 | - | - |
| Enterprise Value (EV) 1 | 237.3 | 184.4 | 276.1 | 857.1 | 1,021 | 1,518 | 1,518 | 1,518 |
| P/E ratio | -4.49 x | -2.22 x | -2.76 x | -11.8 x | -34.8 x | 22.2 x | 13.1 x | 11.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.08 x | 4.37 x | 3.41 x | 5.56 x | 3.96 x | 4.55 x | 3.89 x | 3.51 x |
| EV / Revenue | 8.08 x | 4.37 x | 3.41 x | 5.56 x | 3.96 x | 4.55 x | 3.89 x | 3.51 x |
| EV / EBITDA | - | - | - | - | 25.4 x | 14.7 x | 10.7 x | 8.63 x |
| EV / FCF | - | -1.61 x | -2.41 x | -14.5 x | - | 34.7 x | 12.7 x | 11.6 x |
| FCF Yield | - | -62.2% | -41.5% | -6.91% | - | 2.88% | 7.89% | 8.64% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 59,318 | 94,548 | 195,814 | 220,903 | 225,968 | 231,772 | - | - |
| Reference price 2 | 4.000 | 1.950 | 1.410 | 3.880 | 4.520 | 6.550 | 6.550 | 6.550 |
| Announcement Date | 3/12/20 | 3/25/21 | 3/24/22 | 3/23/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.35 | 42.22 | 80.94 | 154.1 | 258.2 | 333.8 | 390 | 432.3 |
| EBITDA 1 | - | - | - | - | 40.25 | 103.2 | 141.8 | 176 |
| EBIT 1 | -41.42 | -64.91 | -58.37 | -39.37 | 21.63 | 82.12 | 128.1 | 148.7 |
| Operating Margin | -141.14% | -153.75% | -72.12% | -25.55% | 8.38% | 24.6% | 32.86% | 34.41% |
| Earnings before Tax (EBT) 1 | -48.28 | -75.75 | -55 | -65.9 | -28.24 | 67.38 | 116.5 | 141.8 |
| Net income 1 | -48.28 | -75.75 | -71.65 | -65.9 | -28.24 | 67.38 | 113.9 | 135.1 |
| Net margin | -164.5% | -179.41% | -88.52% | -42.77% | -10.94% | 20.19% | 29.22% | 31.25% |
| EPS 2 | -0.8900 | -0.8800 | -0.5100 | -0.3300 | -0.1300 | 0.2950 | 0.5000 | 0.5833 |
| Free Cash Flow 1 | - | -114.7 | -114.6 | -59.23 | - | 43.7 | 119.8 | 131.2 |
| FCF margin | - | -271.74% | -141.56% | -38.44% | - | 13.09% | 30.73% | 30.34% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 42.32% | 84.49% | 74.52% |
| FCF Conversion (Net income) | - | - | - | - | - | 64.85% | 105.18% | 97.08% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/25/21 | 3/24/22 | 3/23/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.68 | 26.38 | 29.1 | 33.91 | 41.05 | 49.98 | 56.91 | 60.12 | 67.27 | 73.9 | 77.28 | 81.28 | 85.65 | 89.68 |
| EBITDA 1 | - | - | - | - | - | - | - | 6.433 | 12.75 | 18.6 | 19.1 | 22.05 | 32.7 | 29.35 |
| EBIT 1 | -14.44 | -13.19 | -14.82 | -9.175 | -9.317 | -6.059 | -0.8133 | -0.4731 | 8.685 | 14.24 | 16.38 | 19.18 | 26.25 | 23.92 |
| Operating Margin | -69.81% | -50% | -50.91% | -27.06% | -22.69% | -12.12% | -1.43% | -0.79% | 12.91% | 19.26% | 21.19% | 23.59% | 30.65% | 26.68% |
| Earnings before Tax (EBT) 1 | -17.71 | -16.65 | -25.01 | -13.76 | -14.9 | -12.23 | -6.789 | -6.371 | 2.565 | -17.64 | 12.43 | 15.44 | 22.61 | 20.47 |
| Net income 1 | -17.71 | -16.65 | -25.01 | -13.76 | -14.9 | -12.23 | -6.789 | -6.371 | 2.565 | -17.64 | 12.43 | 15.44 | 22.61 | 20.47 |
| Net margin | -85.65% | -63.11% | -85.93% | -40.6% | -36.29% | -24.47% | -11.93% | -10.6% | 3.81% | -23.87% | 16.09% | 19% | 26.4% | 22.83% |
| EPS 2 | -0.1300 | -0.0700 | -0.1300 | -0.0700 | -0.0800 | -0.0600 | -0.0300 | -0.0300 | 0.0100 | -0.0800 | 0.0550 | 0.0700 | 0.0975 | 0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/24/22 | 5/11/22 | 8/10/22 | 11/9/22 | 3/23/23 | 5/10/23 | 8/9/23 | 11/8/23 | 2/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -115 | -115 | -59.2 | - | 43.7 | 120 | 131 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 3.81 | 12.7 | 13.5 | 13.9 | 4.77 | 5 | 11 | 11.8 |
| Capex / Sales | 12.99% | 30.14% | 16.69% | 9.03% | 1.85% | 1.5% | 2.83% | 2.74% |
| Announcement Date | 3/12/20 | 3/25/21 | 3/24/22 | 3/23/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.55
USD
Average target price
8.375
USD
Spread / Average Target
+27.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.91% | 1.52B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- ADMA Stock
- Financials ADMA Biologics, Inc.
